Lack of a US Food and Drug Administration Indication Should Not Limit Access to Appropriate Treatment

Editorials in the Journal of the American Academy of Dermatology are not usually intended to be used in a prior approval packet. This one is different. Reply to: "Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment"Journal of the American Academy of DermatologyVol. 81Issue 1PreviewTo the Editor: We recently read with great interest Albrecht et al's commentary on how US Food and Drug Administration (FDA) indications limit treatment access.1 Insurance companies frequently utilize FDA guidelines and drug compendia to dictate treatment coverage; however, these resources are frequently outdated and lacking in scope.2 We agree that treatment coverage should not be restricted by FDA approval. To lend further credence to their declaration, herein we provide evidence of disparity in prior authorization (PA) rates between diseases with and without an FDA-indicated treatment. Full-Text PDF